Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027078 · ClinicalTrials.gov registry record
Mechanism of Endothelial Dysfunction in Obstructive Sleep Apnea (OSA)
A clinical trial, sponsored by Ohio State University.
- Terminated
- Registry status
- 90
- Enrollment target
NCT01027078: Clinical Trial study, sponsored by Ohio State University.
NCT01027078 is a clinical trial that was terminated before completion, run by Ohio State University. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01027078 was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- 90 participants
- Enrollment target
Study Summary
The investigators hypothesized that patients with Obstructive Sleep Apnea (OSA) who are free of any cardiovascular disease will have early microcirculatory changes that are unique to OSA, and therefore would resolve with treatment of OSA.
Primary Outcome
All measurements will be obtained upon diagnosis of OSA and 12 weeks after effective treatment with continuous positive airway pressure (CPAP). Controls will receive all measurements at baseline.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-11 |
| Est. Completion | 2022-02-04 |
Why NCT01027078 stopped before completion
NCT01027078 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01027078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01027078 about?
NCT01027078 is a clinical study titled "Mechanism of Endothelial Dysfunction in Obstructive Sleep Apnea (OSA)". The investigators hypothesized that patients with Obstructive Sleep Apnea (OSA) who are free of any cardiovascular disease will have early microcirculatory changes that are unique to OSA, and therefore would resolve with treatment of OSA.
What is the current status of trial NCT01027078?
This trial is currently terminated. The enrollment target is 90 participants. The study started on 2009-11. Estimated completion is 2022-02-04.
Who is sponsoring clinical trial NCT01027078?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia